Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S.
Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | -0.17 Increased by +39.29% | -0.21 Increased by +19.05% |
| Mar 12, 24 | -0.31 Increased by +18.42% | -0.24 Decreased by -29.17% |
| Nov 2, 23 | -0.19 Increased by +17.39% | -0.23 Increased by +17.39% |
| Aug 3, 23 | -0.24 Increased by +25.00% | -0.23 Decreased by -4.35% |
| May 3, 23 | -0.28 Increased by +30.00% | -0.30 Increased by +6.67% |
| Feb 21, 23 | -0.38 Decreased by -280.00% | -0.17 Decreased by -123.53% |
| Nov 1, 22 | -0.23 Increased by +30.30% | -0.29 Increased by +20.69% |
| Aug 4, 22 | -0.32 Decreased by -33.33% | -0.34 Increased by +5.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 92.76 M Increased by +34.87% | -35.38 M Increased by +33.66% | Decreased by -38.14% Increased by +50.81% |
| Dec 31, 23 | 93.40 M Increased by +17.42% | -61.73 M Increased by +13.71% | Decreased by -66.09% Increased by +26.51% |
| Sep 30, 23 | 86.74 M Increased by +14.39% | -36.15 M Increased by +14.98% | Decreased by -41.67% Increased by +25.68% |
| Jun 30, 23 | 82.49 M Increased by +25.88% | -75.33 M Decreased by -27.98% | Decreased by -91.31% Decreased by -1.67% |
| Mar 31, 23 | 68.78 M Increased by +37.77% | -53.33 M Increased by +28.12% | Decreased by -77.54% Increased by +47.82% |
| Dec 31, 22 | 79.55 M Increased by +68.68% | -71.54 M Decreased by -302.40% | Decreased by -89.94% Decreased by -138.56% |
| Sep 30, 22 | 75.83 M Increased by +84.97% | -42.52 M Increased by +27.69% | Decreased by -56.08% Increased by +60.91% |
| Jun 30, 22 | 65.53 M Increased by +31.17% | -58.86 M Decreased by -36.25% | Decreased by -89.82% Decreased by -3.87% |